Werner Steimer1, Julia M Potter. 1. Institute for Clinical Chemistry and Pathobiochemistry, Munich University of Technology, Klinikum rechts der Isar, Ismaningerstrasse 22, D-81675 Munich, Germany. Steimer@KlinChem.med.TU-Muenchen.de
Abstract
BACKGROUND: Pharmacogenetics is the science of the influence of heredity on pharmacological response. ISSUES: The cost of severe adverse drug reactions in individuals has been estimated in the US alone to be in excess of US$4 billion. It has been argued that in a significant proportion of cases, the efficacy and toxicity profiles of drug therapy would be substantially improved in individuals if characteristics due to genetic variation were taken into account. Methods are now available, which make screening for susceptibility feasible. CONCLUSIONS: There are several therapeutic areas in which screening may give rise to significant improvements in outcome with cost-benefits to both the individual and the community. However, there is currently a lack of data on which cost-benefit analysis can be based. The challenge is to provide this information for new drugs, and for drugs with established therapeutic roles.
BACKGROUND: Pharmacogenetics is the science of the influence of heredity on pharmacological response. ISSUES: The cost of severe adverse drug reactions in individuals has been estimated in the US alone to be in excess of US$4 billion. It has been argued that in a significant proportion of cases, the efficacy and toxicity profiles of drug therapy would be substantially improved in individuals if characteristics due to genetic variation were taken into account. Methods are now available, which make screening for susceptibility feasible. CONCLUSIONS: There are several therapeutic areas in which screening may give rise to significant improvements in outcome with cost-benefits to both the individual and the community. However, there is currently a lack of data on which cost-benefit analysis can be based. The challenge is to provide this information for new drugs, and for drugs with established therapeutic roles.
Authors: Eveline Jaquenoud Sirot; Jan Willem van der Velden; Katharina Rentsch; Chin B Eap; Pierre Baumann Journal: Drug Saf Date: 2006 Impact factor: 5.606
Authors: Emma Gutiérrez de Mesa; Ignacio Hidalgo; Panayotis Christidis; Juan Carlos Ciscar; Eva Vegas; Dolores Ibarreta Journal: Mol Diagn Ther Date: 2007 Impact factor: 4.074
Authors: Pierre Baumann; Sven Ulrich; Gabriel Eckermann; Manfred Gerlach; Hans-Joachim Kuss; Gerd Laux; Bruno Müller-Oerlinghausen; Marie Luise Rao; Peter Riederer; Gerald Zernig; Christoph Hiemke Journal: Dialogues Clin Neurosci Date: 2005 Impact factor: 5.986